Announcement on Obtaining Drug Registration Certificate by Subsidiary
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Obtaining Drug Registration Certificate by Subsidiary
Filed with SSE · · 2 pages · Chinese
Release
Tasly Pharmaceutical Group Co. Ltd. on 6ix
Earlier from Tasly Pharmaceutical
- Announcement on Remuneration Plan for Directors and Senior Management Members in 2026
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
- Announcement on Change of Accounting Policies
- Announcement on Resolutions of the 2025 Annual General Meeting
Later from Tasly Pharmaceutical
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Semi-annual Performance for 2026
- Announcement on a Wholly-owned Subsidiary's Receipt of Clinical Trial Notice for the Extension of the Treatment Time Window for the Acute Ischemic Stroke Indication of Recombinant Human Pro-urokinase for Injection
- Announcement on Amendments to the Articles of Association
- Announcement on Subsidiary Obtaining the Notice of Approval for Clinical Trial
Follow Tasly Pharmaceutical into a list and get an email when it puts out news.
Follow Tasly Pharmaceutical